
Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH
Blood Podcast
00:00
Innovations in Targeting Mutations and Managing Cancer Risks
This chapter explores the innovative monoclonal antibody INCA 033989, which targets calreticulin mutations in myeloproliferative neoplasms, and its potential therapeutic benefits. It also highlights concerning trends in bleeding risks in cancer patients and updates on diagnostic guidelines for familial hemophagocytic lymphohistiocytosis.
Transcript
Play full episode